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Abstract Osteoarthritis (OA) pain is poorly understood and
managed, as current analgesics have only limited efficacy and
unwanted side effect profiles. A broader understanding of the
pathological mechanisms driving OA joint pain is vital for the
development of improved analgesics. Both clinical and preclin-
ical data suggest an association between joint levels of the
sensory neuropeptide calcitonin gene-related peptide (CGRP)
and pain during OA. Whether a direct causative link exists
remains an important unanswered question. Given the recent
development of small molecule CGRP receptor antagonists with
clinical efficacy against migraine pain, the interrogation of the
role of CGRP in OA pain mechanisms is extremely timely. In
this article, we provide the background to the importance of
CGRP in painmechanisms and review the emerging clinical and
preclinical evidence implicating a role for CGRP in OA pain.
We suggest that the CGRP receptor antagonists developed for
migraine pain warrant further investigation in OA.
Keywords Osteoarthritis . Pain . CGRP . CGRP receptor
antagonists . Peripheral sensitization
Introduction
Osteoarthritis (OA) is a chronic degenerative joint disease
characterized by cartilage degeneration, synovial inflamma-
tion and subchondral bone changes including sclerosis and
osteophyte formation, leading to a decline in joint function
[1]. Chronic pain is the main clinical symptom of OA and is
the key factor in patients seeking medical attention. The
underlying mechanisms driving OA pain are not fully under-
stood, and as a consequence many of the commonly pre-
scribed analgesic drugs used to treat OA pain, such as non-
steroidal anti-inflammatory drugs (NSAIDs) and weak opi-
oids, provide variable symptomatic pain relief [2]. A lack of
disease modifying drugs for OA has led to a growing demand
for more effective analgesics. A better understanding of the
mechanisms leading to changes within the nociceptive system
during joint degeneration will help drive forward the devel-
opment of new and improved analgesics that may exert ben-
eficial effects beyond symptom modification.
Clinical evidence indicates that changes in the peripheral
nociceptive system at the level of the OA joint make an
important contribution to the pain experienced. Surgical joint
replacement [3] and intra-articular local anesthetic [4] allevi-
ate pain in around 60–80 % of patients. Further, experimental
studies in OA patients indicate sensitization of joint innervat-
ing nociceptors (peripheral sensitization) duringOA [5••]. The
peripheral mediators of this sensitization have not yet been
identified.
Calcitonin gene-related peptide (CGRP) is a pro-inflammatory
peptide expressed by sensory neurons, including those that
innervate joints [6]. CGRP has long been known to be impor-
tant in the generation of migraine pain and recent clinical trials
have demonstrated efficacy of small molecule CGRP receptor
antagonists against migraine pain [7]. Like migraine, elevated
levels of CGRP, activation of peripheral neurons, and periph-
eral sensitization are all features of OA, suggesting that CGRP
receptor antagonists may have clinical utility in the treatment
of OA pain. However, the importance of CGRP to OA pain
mechanisms and the question of whether these antagonists
might modulate OA pain are only just beginning to be
addressed. This article will provide the background on the
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importance of CGRP in pain mechanisms as well as evidence
for the emerging role of CGRP and its receptor system in
painful OA joints.
CGRP
CGRP is a 37-amino acid neuropeptide formed from the
alternative splicing of the calcitonin gene [8]. CGRP belongs
to a large family of peptides that includes calcitonin, amylin
and adrenomedullin, and is one of the most abundant peptides
within the nervous system. The predominant form of CGRP is
known as α-CGRP. A second isoform of CGRP, β-CGRP, is
produced from a separate gene, but shares high sequence
homology (three amino acids different in man and one in the
rat) [9]. Whilst both isoforms display similar biological and
pharmacological activities, they exhibit significant differences
in their expression patterns; α-CGRP is expressed in both the
peripheral and central nervous system, whilst β-CGRP is
primarily expressed in the enteric nervous system [10]. Little
is known about the physiological significance of the two
CGRP isoforms. CGRP plays a role in a diverse range of
biological functions, but is best known for its role as a potent
vasodilator [11]. Injection of CGRP causes a persistent and
long lasting increase in microvascular blood flow in the skin
[11] and other tissues such as the knee joint [12]. However,
CGRP also has well-established roles in neurogenic inflam-
mation and nociception [13•].
CGRP-like immunoreactivity (CGRP-LI) is found in 40–
50 % of all types of sensory neuronal somata (Aα, Aβ, Aδ,
and C-type fibers) of the dorsal root ganglia (DRG), being
particularly enriched in small nociceptive neurons [14], in-
cluding those that innervate joints [6]. Many of these neurons
co-express substance P (SP) [15]. A significant number of
CGRP-LI neurons are non-nociceptive mechanoreceptors
[16]. CGRP-LI nerve fiber terminals synapse onto lamina I-
II and lamina V of the spinal cord (laminae associated with
nociceptive processing) across a number of species [17],
consistent with the expression of CGRP-LI in mainly small
nociceptive sensory neurons.
The release of CGRP from the peripheral and central
terminals of sensory neurons is Ca2+ dependent, and can be
initiated by noxious mechanical stimulation of the skin [18],
TRPV1 activation [19, 20], electrical stimulation [19, 21, 22•],
noxious heat [23] or protein kinase C (PKC) activation [23].
The release of CGRP into the spinal cord can facilitate the
release of excitatory neurotransmitters, such as glutamate and
aspartate, strengthening connections in the dorsal horn and
promoting synaptic transmission [24]. Thus, the release of
CGRP following noxious stimulation and the promotion of
excitatory neurotransmission in the dorsal horn of the spinal
cord suggests that CGRP has an important role in the trans-
mission of painful stimuli.
The CGRP Receptor System
Until relatively recently, there was believed to be two CGRP
receptor subtypes in existence, differing in their sensitivity to
the classical CGRP receptor antagonist CGRP8-37 [25].
However, following the discovery of the molecular identity
of the composition of the CGRP receptor, it is now widely
held that only one CGRP receptor exists (Fig. 1). The CGRP
receptor was identified following the discovery that when
expressed in HEK293 cells, the orphan Family B GPCR,
calcitonin receptor-like receptor (CLR), showed high affinity
binding sites for CGRP and was pharmacologically respon-
sive to CGRP administration [26]. Shortly after, it was dis-
covered that to fully function, CLR required a single trans-
membrane protein called receptor activity modifying protein 1
(RAMP1), to aid the transport of CLR to the cell surface [27]
(Fig. 1). To date, three isoforms of RAMPs have been identi-
fied, with CLR and RAMP2/3 complexes forming
adrenomedullin receptors [28]. Thus, the formation of multi-
ple calcitonin receptors is possible, raising the intriguing
possibility that under certain conditions (i.e. disease), there
may be a dynamic regulation of RAMP isoform expression
governing tissue pharmacology.
A third, intracellular receptor component protein (RCP) is
also required to facilitate CGRP receptor signaling and couple
the receptor to secondary messenger pathways [29] (Fig. 1).
CGRP receptor activation results in an increase in intracellular
cAMP and subsequent protein kinase A (PKA) activation,
mediated by the G protein Gαs [30]. However, signaling
through other G proteins is possible, and CGRP receptor
signaling has been shown to result in the activation of nitric
oxide (NO) [31], mitogen activated protein kinases (MAPK)
[32], phospholipase C [33], PKA and PKC [34].
Fig. 1 CGRP receptor composition. The CGRP receptor is a hetero-
trimeric protein comprised of the GPCR calcitonin receptor-like receptor
(CLR), coupled to a receptor activity modifying protein (RAMP). There
are three RAMP isoforms that govern receptor pharmacology; RAMP1
containing receptors are CGRP-binding, whilst RAMP2/3 containing
receptors are adrenomedullin-binding .The intracellular receptor compo-
nent protein (RCP) facilitates secondary messenger signaling. Different
tissues/cells can express multiple RAMP isoforms, resulting in a complex
pharmacological profile
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CGRP receptor components are expressed in tissues at all
levels of the pain pathway [35–39]. Receptor component
expression is primarily on small-medium sized Aδ and C-
type DRG neurons, some of which co-express CGRP [36,
38]. These neurons are typically thought to be nociceptive,
highlighting a potential role for the CGRP receptor in the
modulation of peripheral nociception. Interestingly, RAMP1
has been shown to be functionally rate limiting for the effects
of CGRP on trigeminal ganglia, and elevated levels in man
may sensitize to the effects of CGRP during migraine [40].
The expression of CGRP receptors on CGRP expressing
sensory neurons indicates the existence of CGRP auto-
receptors, which may regulate the neurogenic inflammatory
and nociceptive properties of CGRP. Whether CGRP receptor
components are expressed by sensory neurons innervating
joints is currently unknown. Within the spinal cord dorsal
horn, CLR and RAMP1 expression is primarily in laminae I
and II where Aδ and C-type nociceptors terminate [38]. It is
not known whether this CLR and RAMP1 immunoreactivity
originates from spinal neurons or primary afferent terminals.
The Role of CGRP in Acute Nociceptive Transmission
Ever since the demonstration of expression of CGRP on small
nociceptive afferents and within the dorsal horn of the spinal
cord 30 years ago [41], there has been growing interest in the
role of CGRP in the transmission of nociceptive information
and the generation of pain. The role of CGRP in modulating
nociceptive transmission at central sites is well accepted.
Although, within the brain, the effects of CGRP receptor acti-
vation on pain responses appears to be site specific; CGRP
receptor activation within the amygdala evokes pain behavior
and facilitates excitatory synaptic transmission [42, 43], whilst
CGRP applied to the periaqueductal grey, nucleus accumbens
and nucleus raphe magnus is antinociceptive [44–49].
Spinally applied CGRP facilitates excitatory synaptic
transmission at the level of the spinal cord, potentiating spinal
N-methyl-D-aspartate (NMDA) responses [50] and sensitiz-
ing spinal neurons [34, 51, 52], increasing their discharge
frequency to mechanical and electrical stimulation and poten-
tiating their responses to SP [52–54]. Behaviorally, intrathecal
CGRP in the rat produces mechanical and thermal
hyperalgesia as well as mechanical allodynia [34, 54, 55].
Some groups have however published conflicting data on
the spinal role of CGRP, demonstrating a lack of effect of
CGRP on the excitability of spinal cord neurons [56] and lack
of hyperalgesic effect of intrathecal CGRP [57, 58]. These
discrepancies could relate to methodological differences (e.g.
type of CGRP used with respect to α vs. β analogs).
Despite this compelling evidence, the role of CGRP in the
modulation of peripheral nociceptive responses is less well
accepted. In vitro studies have provided evidence that CGRP
can directly modulate nociceptor excitability. CGRP depolar-
izes cultured sensory neurons [59] and enhances tetrodotoxin
resistant (TTX-R) voltage gated sodium currents (TTX-R
NaVs) via a PKA-dependent and PKC-dependent phosphory-
lation of NaV1.8 [60]. Administration of CGRP to cultured
DRG neurons lowered their activation thresholds and in-
creased their excitability by enhancing TTX-R NaV current
density, lowering the amount of current required to evoke an
action potential and shifting voltage and conductance curves
in a hyperpolarized direction [60]. These effects are neuro-
physiologic hallmarks of peripheral sensitization, suggesting
that CGRP has the potential to drive maladaptive processes in
peripheral nerves, leading to pain. Despite this in vitro evi-
dence for a direct modulation of nociceptor function, evidence
for a direct effect of CGRP on primary afferent nociceptors
in vivo is lacking. CGRP may indirectly contribute to sensi-
tization of nociceptors by evoking the release of pro-
inflammatory mediators from immune cells and nerves, such
as bradykinin and prostaglandins, which can directly excite
and sensitize nociceptors [61–63]. Collectively, these studies
provide putative mechanisms by which CGRP may modulate
peripheral nociception.
In vivo studies have provided support for an important role
of CGRP in peripheral nociceptive mechanisms. The differ-
ential sensitivity of multiple strains of mice to noxious heat
has been attributed to variations in CGRP expression levels in
sensory neurons [64]. These compelling findings suggest that
peripheral CGRP expression is a critical determinant of nox-
ious heat sensitivity. Intra-plantar injection of CGRP evokes
mechanical allodynia, highlighting a sensitizing effect of
CGRP on cutaneous afferents [65]. However, the allodynic
effects of CGRPwere tenfold less potent than SP. In a separate
study, a single injection of CGRP into the rat hind paw
produced only a weak hyperalgesic response (compared to
neurokinin A and SP). However, repeated sub-thresholds
injections of CGRP appeared to prime primary afferent fibers
to a subsequent challenging dose of CGRP, and induced an
intense and long-lasting hyperalgesic response [66]. The po-
tentially important implications of this are that during certain
maladaptive disease processes associated with prolonged re-
lease of CGRP (e.g. OA), the hyperalgesic priming potential
of CGRP may be important for the transition from acute to
chronic pain [67].
Antinociceptive Effects of CGRP Receptor Antagonists
Blocking the effects of endogenous CGRP within the spinal
cord supports a role for CGRP in spinal nociceptive transmis-
sion. Intrathecal administration of the truncated peptide antag-
onist of CGRP, CGRP8-37, inhibits capsaicin induced central
sensitization of spinal dorsal horn wide dynamic range
(WDR) neurons [68] and reduces WDR neuron activity to
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electrical stimulation of the hind paw [53, 69]. Behaviorally,
intrathecal CGRP8-37 inhibits SP-induced [57] and thermal
injury-induced [70] mechanical and thermal hyperalgesia, and
anti-serum raised against CGRP is antinociceptive when ad-
ministered by the intrathecal [56, 71] or intravenous [72] route.
Blocking the actions of CGRP at the level of the spinal cord
is hyperalgesic in models of inflammatory pain. In the kaolin
and carrageenan model of arthritis, spinal administration of
CGRP8-37 inhibits electrically evoked spinal neuronal
hyperexcitability, but has no effect on normal transmission
[51], and spinal administration of the small molecule CGRP
antagonist BIBN4096BS inhibits the responses of amygdala
neurons to mechanical stimulation of the inflamed joint, but not
to stimulation of the normal control joint [45]. Following the
induction of inflammatory arthritis, levels of RCP in the dorsal
horn of the spinal cord are elevated [36]. This increased ex-
pression of RCP may facilitate intracellular signaling through
the CGRP receptor, contributing to the increased sensitivity to
CGRP during inflammatory arthritis. BIBN4096BS inhibits
mechanical evoked activity of WDR neurons in the Complete
Freund’s Adjuvant (CFA) model of cutaneous inflammatory
pain following both systemic and topical (hind paw) adminis-
tration, but has no effect when applied directly to the spinal
cord [13•]. Although the authors did not directly investigate the
site of action, the pharmacokinetics of the compound and the
equal effectiveness of both topical and systemic applications
suggest a peripheral site of action. These preclinical animal
model studies suggest that CGRP receptor antagonists may
have therapeutic potential for the treatment of pain during
inflammation. In addition, the periphery may be an important
site of action of these compounds.
CGRP and Migraine Pain
Migraine is considered a chronic neurovascular disorder char-
acterized by recurrent severe headaches, associated with nau-
sea, vomiting, photophobia and phonophobia, which may be
preceded by an aura [73]. Studies have shown that the pain
arising during migraine is generated by small unmyelinated
fibers, originating from the trigeminal nerve, which surround
cerebral blood vessels [74]. These fibers contain CGRP and SP
[75]. CGRP is released from trigeminal ganglia neurons in vitro
following their stimulation [76]. A number of key data support
an important role for CGRP in the generation of migraine pain;
1) electrical stimulation of the trigeminovascular system results
in the release of CGRP from nociceptive trigeminal afferents
[77]; 2) CGRP levels are elevated in blood samples taken from
patients during migraine attacks [78]; 3) intravenous CGRP
infusion causes headaches and migraines in migraineurs [79];
and 4) small molecule CGRP receptor antagonist are successful
at alleviating pain during acute migraine attacks [80, 81]. The
effects of these small molecule CGRP receptor antagonists
have been investigated in animal models of migraine pain,
revealing a complex mechanism of action involving both pe-
ripheral and central sites. CGRP receptor antagonists reduce
spontaneous and evoked neuronal activity from the spinal
trigeminal nucleus (STN; thought to have an important role in
centrally mediated migraine pain) [82] and inhibit nitric oxide
induced sensitization of the STN [83]. In addition, CGRP
receptor antagonists inhibit electrically evoked activity of
nociceptors of the trigeminocervical complex [84] and reduce
CGRP mediated trigeminovascular neurogenic inflammation
[85]. It appears that within the setting of migraine pain, CGRP
has a role in modulating nociceptive responses both at periph-
eral and central levels. The balance of the relative importance
of CGRP at these sites is unknown [7].
Evidence for a Role of CGRP in Osteoarthritis Pain
Over recent years, both clinical and preclinical evidence indi-
cating an important association between joint levels of CGRP
and pain during OA has been accumulating [6, 13•, 20, 22•,
86–92]. Sensory neurons expressing CGRP innervate most
joint structures [93], particularly the synovial membrane, lig-
aments and subchondral bone [6, 86, 94]. Clinical data from
knee and hip OA patients support an association between joint
CGRP and pain. Perivascular nerve fibers showing CGRP-LI
in the outer region of the menisci of knee OA patients are
increased in density in patients with high chondropathy and
joint pathology [87]. The vascularization and consequent in-
nervation of CGRP expressing nociceptors in joint structures
close to aneural tissue (e.g. cartilage) may provide a mecha-
nism for pain in these patients. Patients with painful OA of the
hip have an increased density of CGRP (and SP)-containing
nerve fibers in the joint capsule compared to asymptomatic
controls [88]. Furthermore, patients with a painless failed hip
arthroplasty completely lacked CGRP-LI fibers surrounding
the joint. The number of synovial CGRP-LI free nerve fibers
and endings is greatest in the medial joint compartment [89].
This compartment is where pain is localized and synovitis and
joint pathology are the greatest. Although these human data
provide evidence for an association between altered joint
CGRP levels and pain during OA, whether there is a direct
causative link remains an important unanswered question.
Studies in preclinical animal models of OA are beginning to
address this question.
The monosodium iodoacetate (MIA) model of OA pain has
gathered favor recently, as a robust and reliable model of OA
that mirrors key components of human knee OA, including
joint pathology [95], pain responses [96, 97], inflammation
[96, 98] and analgesic responsiveness [96, 97]. These changes
are associated with increases in excitability of joint-associated
nociceptors; specifically, an increase in C-fiber spontaneous
activity and an increase in the mechanosensitivity of Aδ-fibers
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[99]. This sensitization is likely to be an important contributor to
the ongoing pain in this model of OA, and there is evidence to
suggest that CGRP may play an important role in the establish-
ment and maintenance of these sensitized responses. Using
back-labeling techniques to identify knee joint afferent cell
bodies in DRGs, it has been shown that CGRP expression is
increased in these neurons following MIA treatment [6, 90, 91].
Following MIA, CGRP expression increases specifically in
medium to large diameter neurons that give rise to Aδ-fiber
andAβ-fiber joint afferents, respectively [91]. Concomitant with
this increase in the expression of CGRP, there is also an increase
in the basal and evoked release of CGRP from primary afferent
fibers into the spinal cord [20, 22•]. The increased expression
and release of CGRP during MIA-induced OA may sensitize
TTX-R NaV1.8 channels (see above). Indeed, blocking NaV1.8
on knee joint-associated afferents reduces mechanical
hyperalgesia in the MIA model [100]. Ablation of CGRP ex-
pressing nerve terminals by capsaicin treatment prior to MIA
injection reduces pain behavior and bone pathology [92]. The
ablated afferents also express other nociceptive neuropeptides
and neurotransmitters, so further work is needed to investigate
whether there is a direct link between reduced joint CGRP levels
and protection against OA pain.
A recent behavioral study carried out in the MIA model
demonstrated analgesic effects of the small molecule receptor
antagonist BIBN4096BS. Sub-cutaneous treatment with
BIBN4096BS reversed MIA-induced weight bearing asym-
metry as effectively as morphine [13•]. Given the relatively
poor capacity for BIBN4096BS to penetrate the blood brain
barrier, the authors hypothesized that the reversal of pain
behavior was peripherally mediated, although the investiga-
tion of a peripheral site was not further examined in this model
and BIBN4096BS effects were only assessed during the acute
inflammatory phase (day 3 post-MIA) before OA-like
changes are established. Thus, further investigations of the
role of CGRP in driving peripheral nociceptive inputs during
OA are required. These preclinical studies in the MIA model
highlight the potential importance of CGRP in driving aber-
rant nociceptive inputs from the joint and pain in this model.
Conclusions
There is now compelling evidence to suggest that elevated
peripheral CGRP expression and release during joint degenera-
tion may play an important role in the establishment of periph-
eral sensitization and the pain associated with OA. Augmented
release of CGRP from the peripheral terminals of nociceptors
within the degenerating joint may activate CGRP receptors
expressed by these neurons, directly activating them and driving
their sensitization via downstream phosphorylation of ion chan-
nels, and indirectly activating them by promoting the release of
proinflammatory and sensitizing molecules. The concomitant
augmented release of CGRP from the central terminals of
nociceptors within the dorsal horn would also be expected to
facilitate nociceptive transmission. Similar to migraine pain, it
appears that CGRP may have important roles at both peripheral
and central levels during OA pain.
Further studies are required to fully understand the role that
CGRP and associated regulatory proteins play in the genera-
tion of OA pain. Dissecting the complex role of CGRP,
including the relative importance of CGRP at peripheral and
central sites, may lead to more effective and targeted thera-
peutics. Blocking the interaction of CGRP and its receptor
complex in the periphery may be an attractive therapeutic
strategy for the alleviation of OA pain without the side effects
of NSAIDs. Vital to this will be a broader understanding of the
role that the CGRP receptor system plays in the development
of peripheral sensitization and pain in OA.
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